The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

Health groups led by the American Academy of Pediatrics filed a lawsuit against HHS Secretary Robert F. Kennedy Jr. on Monday ...

KalVista Pharmaceuticals KALV saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 62 to 90. Please watch the video at Investors.com - Do Your Stocks Meet ...

A Senate committee will vote this week on whether to advance the nomination of Susan Monarez, President Donald Trump’s pick ...

Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older ...

S&P Global Ratings is considering whether to reclassify Centene Corp.'s credit ratings to junk, which would strongly impact its borrowing power. Centene, the top seller of ACA health plans, is ...

DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) ("DRI Healthcare") today announced KalVista Pharmaceuticals ("KalVista") has disclosed it has received approval from the U.S. Food and Drug ...

As per provisional closing data, the barometer index, the S&P BSE Sensex, added 270.01 points or 0.32% to 83,712.51. The Nifty 50 index rose 61.20 points or 0.24% to 25,522.50.

Citizens JMP analyst Jonathan Wolleben raised the firm’s price target on KalVista (KALV) to $27 from $19 and keeps an Outperform rating on the ...

IST, the barometer index, the S&P BSE Sensex, declined 20.01 points or 0.02% to 83,460.19. The Nifty 50 index lost 9.05 points or 0.03% to 25,452.25.